Sandoz Group AG Sponsored ADR (OTCMKTS:SDZNY) Short Interest Up 73.3% in August

Key Points

• Sandoz Group AG's short interest increased significantly by 73.3% in August, rising from 38,900 shares at the end of July to 67,400 shares.
• The company's stock price recently reached $61.42, with a 12-month high of $63.72 and a low of $35.61.
• Jefferies Financial Group downgraded Sandoz Group from a "strong-buy" rating to a "hold" rating, with the average rating now being "Hold" from multiple analysts.

Sandoz Group AG Sponsored ADR (OTCMKTS:SDZNY - Get Free Report) was the recipient of a significant increase in short interest during the month of August. As of August 15th, there was short interest totaling 67,400 shares, an increase of 73.3% from the July 31st total of 38,900 shares. Based on an average daily volume of 46,800 shares, the short-interest ratio is currently 1.4 days. Based on an average daily volume of 46,800 shares, the short-interest ratio is currently 1.4 days.

Sandoz Group Trading Down 0.4%

OTCMKTS SDZNY traded down $0.23 on Wednesday, reaching $60.47. The stock had a trading volume of 9,747 shares, compared to its average volume of 23,254. The company has a debt-to-equity ratio of 0.57, a quick ratio of 0.79 and a current ratio of 1.24. The firm has a fifty day moving average of $58.99 and a two-hundred day moving average of $50.22. Sandoz Group has a 1-year low of $35.61 and a 1-year high of $63.72.

Analyst Upgrades and Downgrades

Separately, Jefferies Financial Group downgraded shares of Sandoz Group from a "strong-buy" rating to a "hold" rating in a report on Friday, August 8th. Three research analysts have rated the stock with a Hold rating, According to MarketBeat.com, Sandoz Group presently has an average rating of "Hold".

Sandoz Group Company Profile

Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, diabetes, immunology, endocrinology, hematology, and ophthalmology, as well as bone disease.